Edition:
United Kingdom

Arrowhead Pharmaceuticals Inc (ARWR.OQ)

ARWR.OQ on NASDAQ Stock Exchange Global Select Market

13.05USD
19 Oct 2018
Change (% chg)

$-0.30 (-2.25%)
Prev Close
$13.35
Open
$13.53
Day's High
$13.69
Day's Low
$12.81
Volume
885,594
Avg. Vol
731,137
52-wk High
$22.38
52-wk Low
$3.01

Select another date:

Thu, Oct 4 2018

Photo

J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion

Arrowhead Pharmaceuticals Inc said on Thursday Johnson & Johnson would develop and market its gene-silencing Hepatitis B treatment and buy a minor stake in a deal that could be potentially worth more than $3.7 billion (2.8 billion pounds), sending its shares surging 20 percent.

J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion

Arrowhead Pharmaceuticals Inc said on Thursday Johnson & Johnson would develop and market its gene-silencing Hepatitis B treatment and buy a minor stake in a deal that could be potentially worth more than $3.7 billion, sending its shares surging 20 percent.

UPDATE 1-J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 bln

* Shares gain as much as 20 pct premarket (Adds share movement and comment from analyst, CEO)

J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 bln

Oct 4 Arrowhead Pharmaceuticals Inc said on Thursday Johnson & Johnson would develop and market its gene-silencing Hepatitis B drug and pick up a minor stake in the company in a deal that could be potentially worth more than $3.7 billion.

BRIEF-Arrowhead Pharmaceuticals Presents Preclinical Data On Expanding Cardiometabolic Pipeline

* ARROWHEAD PHARMACEUTICALS PRESENTS PRECLINICAL DATA ON EXPANDING CARDIOMETABOLIC PIPELINE

BRIEF-Arrowhead Pharmaceuticals Reports Qtrly Loss Per Share $0.18

* ARROWHEAD PHARMACEUTICALS REPORTS FISCAL 2018 SECOND QUARTER RESULTS

Select another date: